Skip to main content
Equibles
ENTA logo

ENTA · Enanta Pharmaceuticals Inc · Metrics

Track ENTA — free

Use ENTA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ENTA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$11.94 -0.24 (-1.97%) Q2 2024 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$354.75M
Shares
29.13M
Volume · Oct 27 319.44K Avg daily vol (3M) 243.4K

ENTA metrics

71 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$12.18
Market cap
$354.75M

Price action

20 metrics
Price change (1W)
+4.4%
Price change (30D)
-3.4%
Price change (3M)
-3.4%
Price change (6M)
-11.2%
Price change (YTD)
-22.8%
Price change (1Y)
+16.0%
Trailing year
Price change (5Y)
-84.8%
52-week high
$16.85
52-week low
$10.47
Change from 52-week high
-27.7%
Change from 52-week low
+16.3%
Annualized volatility
47.7%
Annualized volatility (3M)
44.3%
Beta
0.9
RSI (14D)
51.3
Price vs SMA 50
-3.8%
Price vs SMA 200
-7.9%
Avg volume (3M)
243,398
Relative volume
1.3
Average dollar volume
$3.11M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
29.13M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
5.4×
reciprocal yield 18.4%
P / book
3.5
reciprocal yield 28.5%
FCF yield
-10.4%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-17.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2024-11-25

Profitability

9 metrics
Gross margin
—
Operating margin
-90.0%
Trailing 12 months
Net margin
-96.9%
Gross profit (TTM)
—
Operating profit (TTM)
−$58.73M
Net income (TTM)
−$63.23M
Trailing 12 months
Diluted EPS (TTM)
$-2.42
FCF margin
-56.6%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$3.03

Growth

11 metrics
Revenue growth YoY
-21.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$65.26M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+36.1%
Year over year · more shares
Revenue CAGR (3Y)
-8.8%
Revenue CAGR (5Y)
-11.8%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-62.6%
Return on assets
-21.3%
Debt / equity
—
Current ratio
3.8
EBITDA (TTM)
−$53.82M
Free cash flow (TTM)
−$36.94M
Quick ratio
3.8
Interest coverage
-4.5
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$33.42M
Latest balance sheet
Cash & equivalents
$33.42M
Total assets
$296.87M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$35.32M
Capital expenditures (TTM)
$1.62M
R&D (TTM)
$86.24M
SG&A (TTM)
—
Stock compensation (TTM)
$15.28M
R&D / revenue
132.1%
Stock compensation / revenue
23.4%

Ownership (13F)

9 metrics
13F filers
122
13F filer change QoQ
-11
Institutional ownership
93.8%
Conviction holders (share of 13F filers)
0.8%
Crowding (high-turnover and private-fund holders)
40.0%
Private-fund adviser ownership
39.5%
Active holders' share change QoQ
+0.1%
Holder tenure
12.5
Price vs estimated holder cost
+20.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
13.7%

Short interest

3 metrics
Short interest
7.8%
Latest settlement · 8.6 days to cover
Days to cover
8.6d
Short-squeeze score
60 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1177648 CUSIP 29251M106 13F (30d) 15 filings 15 filers Visit website Investor relations